TNFRSF4 and cancer: In particular, imaging active T-cells, using an anti-OX40 radiotracer, in a model of cancer treated with CpG vaccination/adjuvant therapy, clearly showed the TDLN persistent enhanced signal throughout the treatment period (on days 2 and 9 after treatment) (38).